-/low tumor cells in the DCIS components of IDC and DCIS might harbor different biology, which may lead to differences in cancer progression and early carcinogenesis. Breast cancer is a highly heterogeneous disease, which displays varying molecular and clinical features, and therapeutic resistance is a frequently encountered problem. The cancer stem cell (CSC) hypothesis was proposed to explore the cause of breast cancer's diverse genetics and pathological patterns. According to this hypothesis, only rare CSCs have indefinite proliferative potential and drug resistance that drives tumor progression and recurrence.
2 Although non-CSCs actively proliferate and constitute the majority of tumor volume, they are differentiated and destined to die. This hypothesis is very attractive, because a therapeutic strategy directed at CSCs would be very useful.
Since The clonal evolution model suggests that tumor cell phenotypes are determined by a combination of an originating cell type of the tumor-initiating cells, acquired genetic and epigenetic alterations, and microenvironmental effects. Thus, in the clonal evolution model, all tumor cells show unstable phenotypes and have the capacity for self-renewal, progression, and drug resistance. Despite a plethora of breast cancer studies, no consensus exists concerning the heterogeneity of breast cancer.
In this study, we investigated the prevalence of CD44 + /CD 24 -/low tumor cells in human breast cancer and analyzed the clinicopathological significance and prognostic value of this cell type.
MATERIALS AND METHODS

Patients
One hundred patients with breast cancer who were diagnosed with invasive ductal carcinoma (IDC) and 45 breast can-cer patients who were diagnosed with ductal carcinoma in situ (DCIS) at Kyung Hee University Medical Center from 2000 to 2007 were recruited into the study. Every case was diagnosed from surgically-resected specimens, and clinical data were collected by retrospective review. Results of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2/Neu) status were also obtained from medical records. ER and PR immunoreactivity was evaluated according to the Allred scoring method. 6 For Her2/Neu immunoreactivity, only membranous staining was scored according to criteria defined in the HerceptTest (DAKO, Carpinteria, CA, USA) protocol.
7 Her2/Neu-positive was defined as 3+ on immunohistochemistry (IHC) or 2+ and fluorescence positivity on in situ hybridization (FISH) testing.
Immunohistochemistry
Tumor blocks were selected after an initial review of hematoxylin and eosin-stained slides to confirm representative tumor lesions. CD44 and CD24 IHC was conducted using the double staining method. Procedures were performed on 4 mm-thick tissue sections using a biotin-free polymeric horseradish peroxidase-linker antibody conjugate system in a Bond-max automatic slide staining system (Vision BioSystems, Mount Waverley, VIC, Australia), according to the manufacturer's instructions with minor modifications. Briefly, 4 mm-thick formalin-fixed and paraffin-embedded tissue sections were deparaffinized with Bond Dewax solution (Vision BioSystems), and an antigen retrieval procedure was conducted using Bond ER solution (Vision BioSystems) for 30 minutes at 100℃. Endogenous peroxidase was quenched by incubation with hydrogen peroxide for 5 minutes. Sections were incubated for 15 minutes at ambient temperature with a 1 : 6,000 dilution of CD44 primary monoclonal antibody (156-3C11, Neomarkers, Fremont, CA, USA), using the Bond Intense R detection kit (Vision BioSystems). Sections were incubated for 15 minutes at ambient temperature with a 1 : 200 dilution of CD24 primary monoclonal antibody (SN3b, Neomarkers), using the Bond Polymer AP Red detection kit (Vision BioSystems). Nuclei were counterstained with hematoxylin.
Evaluation of immunohistochemical staining
Histological sections were examined by two independent investigators (SJ Lim and JY Sung) blinded to the patient clinical data. All invasive components (100 of 100 IDC cases) and DCIS components (44 of 100 IDC cases) were evaluated separately. Membranes were stained brown and red for CD44 and CD24, respectively. Tumor cells showing brown staining on their membranes in the absence of a distinct red color were counted as CD44 + /CD24 -/low tumor cells (Fig. 1 ). An almost entire staining of the individual tumor cell membrane was considered positive. , the sensitivity and specificity for the outcome was plotted to generate an ROC curve. The point on the curve that maximized the sensitivity and specificity of the cell proportions with CD44 + /CD24 -/low for each clinicopathologic parameter (i.e., with the shortest distance -/low cells and various clinicopathologic parameters of the patients with IDC and DCIS, respectively. Kaplan-Meier plots were used to estimate the overall survival (OS) of all patients with IDC. The log-rank test was used to compare the OS of the patient subgroups. Survival plots were constructed using the KaplanMeier method. The independent t-test was also used to compare means between proportions of CD44 + /CD24
-/low tumor cells in 45 DCIS cases and DCIS components in 44 IDC. All tests were two-sided. Differences were considered statistically significant when the p-value was < 0.05.
RESULTS
Patient characteristics
The characteristics of the 100 patients with IDC and the 45 patients with DCIS are summarized in Table 1 . The characteristics of the 44 patients with DCIS components in IDC (data not shown in Table 1 -/low tumor cells were present in the DCIS cases than in the DCIS components of IDC (p < 0.001) ( Table 3) . In a study comparing gene expression and genetic profiles of CD44 + and CD24 + cells isolated from tumors and normal breast tissue, CD44 + cells (known as stem cell markers) were predicted to be more invasive and angiogenic than CD24 + cells. 9 Besides, CD24 mRNA expression is low in invasive breast cancer cell lines compared with non-invasive cell lines. 10 These observations could explain our result that tumors with a preponderance of CD44 + /CD24 -/low tumor cells tended to metastasize more frequently.
This study revealed a high prevalence of CD44 + /CD24 -/low in tumor cells, which was correlated with negative ER status in breast cancer. This result is not surprising, given that stem cells are characterized by a self-renewal capacity and represent a prior stage of differentiation. However, two investigations using mouse mammary stem cells showed contradictory results; ER and PR expression in potential mammary stem cells in one study and no ER or PR expression in a basal population enriched in mouse mammary stem cells in the other. 11, 12 Another study involving 136 human breast cancer specimens found no association between Basal-like feature is determined by no immunoreactivity for both ER and Her2/Neu. ER, estrogen receptor; PR, progesterone receptor; Her2/Neu, human epidermal growth factor receptor 2. 
CD44
+ /CD24 -/low tumor cells and ER and PR expression. 8 In a study undertaken to explain this discrepancy of ER and PR expression and the stem cell population, breast cancers were classified by ER expression into type 1 (stem cell origin, ER negative, undifferentiated histology), type 2 (stem cell origin, ER heterogeneous, intermediately differentiated histology), and type 3 (ER positive progenitor cell origin, ER positive, differentiated histology). 13 According to these authors, because adult stem cells are slowly dividing and long-living with high proliferative capacity, they are able to undergo multiple mutations during carcinogenesis. So, different molecular signatures and clinical behaviors such as ER or PR status can be generated by mutations in normal stem or progenitor cell populations. In this study, similar to type 1 breast cancer according to the classification of Dontu et al., 13 -/low tumor cells in the DCIS components and invasive components in IDC, the role of the former appeared to be involved in cancer progression rather than cancer initiation, which was different from that in pure DCIS.
As mentioned above, our observations suggest that the high prevalence of CD44 -/low cells were correlated with aggressiveness, such as metastasis and negative ER status. The results of a study conducted by Abraham et al. 8 and that of the current study suggest that the proportion of CD44 + /CD24 -/low tumor cells failed to demonstrate prognostic value. We hypothesize that a possible reason for this failure is the great complexity of tumorigenesis, which entails heterogeneity of tumor cell phenotypes and a diversity of predictive factors for tumor progression and therapeutic responsiveness. Therefore, it is thought that breast cancer carcinogenesis could be better understood when it is considered not only in terms of the CSC hypothesis, but also in the context of epigenetic events and the surrounding microenvironment.
Recent reports have suggested that the heterogeneity of CSC phenotypes provides clues to explain the absence of a correlation between CD44 + /CD24 -/low tumor cells and OS in patients with breast cancer. Sheridan et al. 15 reported that many basaltype mammary carcinoma cell lines contain CD44 + /CD24 -/low tumor cells, whereas luminal cell lines do not. Similar to that report, we also found a tendency between the IDC group, with a high prevalence of CD44 + /CD24 -/low cells, and the absence of both ER and Her2/Neu, which is suggestive of a basal-like breast cancer immunophenotype. However, the difference was not statistically significant. Furthermore, the use of mouse BRCA1 knockout models has provided evidence for the existence of heterogeneous CSC populations (CD44 + /CD24 -/low tumor cells and CD133 expression). 16 When aggregate information about CSC heterogeneity is obtained in the future, it may be possible to elucidate a more precise role for CD44 + /CD24 -/low tumor cells. Studies concerning CSCs have become a subject of attention, because stem cells tend to be more resistant to chemotherapeutics than differentiated cells. 17 This difference may be related to high expression levels of anti-apoptotic proteins or ATP-binding cassette transporters, such as the multi-drug resistance gene.
18-20
Therefore, CSCs can also be envisioned as resistant to chemotherapy. Indeed, it has been demonstrated that CD44 + /CD24 -/low BCSCs are more resistant to radiation. 21 More frequent negative hormonal receptor status and these findings concerning BCSCs may explain recurrence and distant metastasis after conventional therapy. Therefore, to devise more effective treatment, additional studies are required to clarify the characteristics and clinicopathologic value of breast cancer stem cells.
In this study, we determined that IDC with a high prevalence of CD44 + /CD24 -/low tumor cells correlated with aggressive features, such as ER negativity and higher grade, although these features had no prognostic value, similar to Abraham et al. 8 This concordance suggests that it may be difficult to understand breast cancer carcinogenesis through the CSC hypothesis of CD44 + /CD24 -/low tumor cells alone. We also found that the proportion of CD44 + /CD24
-/low tumor cells in the DCIS components of IDC and DCIS was significantly different. This finding implies that the role of CD44 + /CD24
-/low tumor cells in DCIS might be different whether it exists in pure DCIS or not.
Although our study had some limitations, the results could contribute to a further understanding of clinical data concerning CD44 
